Home > Insider Trading > Filing (0000899243-18-020515)

Filing Details

Accession Number:: 0000899243-18-020515
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-07-24 16:46:59
Reporting Period:: 2018-07-23

Accepted Time:: 2018-07-24 16:46:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1434418	Constellation Pharmaceuticals Inc	CNST	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue, 54Th Floor New York NY 10022	No	No	Yes	No
1673892	Orbimed Global Healthcare Gp Llc	601 Lexington Avenue, 54Th Floor New York NY 10022	No	No	Yes	No
1682115	Orbimed Capital Gp Vi Llc	601 Lexington Avenue, 54Th Floor New York NY 10022	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-07-23	317,921	$0.00	317,921	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-07-23	100,000	$15.00	417,921	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2018-07-23	317,921	$0.00	317,921	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-07-23	100,000	$15.00	417,921	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series F Preferred Stock	Disposition	2018-07-23	3,500,000	$0.00	317,921	$0.00
Common Stock	Series F Preferred Stock	Disposition	2018-07-23	3,500,000	$0.00	317,921	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

On July 23, 2018, the Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
These securities are held of record by OrbiMed Global Healthcare Master Fund, L.P. OrbiMed Global Healthcare GP LLC is the sole general partner of OrbiMed Global Healthcare Master Fund, L.P., and OrbiMed Advisors LLC is the managing member of OrbiMed Global Healthcare GP LLC. By virtue of such relationships, OrbiMed Global Healthcare GP LLC and OrbiMed Advisors LLC may be deemed to have voting and investment power over the securities held by OrbiMed Global Healthcare Master Fund, L.P. and as a result may be deemed to have beneficial ownership over such securities.
These securities are held of record by OrbiMed Private Investments VI, LP. OrbiMed Capital GP VI LLC is the sole general partner of OrbiMed Private Investments VI, LP, and OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP VI LLC. By virtue of such relationships, OrbiMed Capital GP VI LLC and OrbiMed Advisors LLC may be deemed to have voting and investment power over the securities held by OrbiMed Private Investments VI, LP and as a result may be deemed to have beneficial ownership over such securities.
This report on Form 4 is jointly filed by OrbiMed Capital GP VI LLC, OrbiMed Global Healthcare GP LLC and OrbiMed Advisors LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.